PubMed:23561918
Annnotations
{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/23561918","sourcedb":"PubMed","sourceid":"23561918","source_url":"https://www.ncbi.nlm.nih.gov/pubmed/23561918","text":"Prevalence and outcomes of intermediate saphenous vein graft lesions: findings from the stenting of saphenous vein grafts randomized-controlled trial.\nBACKGROUND: We sought to examine the prevalence and progression rate of intermediate saphenous vein graft (SVG) lesions in the Stenting Of Saphenous vein grafts (SOS) trial.\nMETHODS: The baseline and follow-up angiograms of 80 patients participating in the SOS trial were analyzed to determine the prevalence of intermediate (30-60% angiographic diameter stenosis) SVG lesions and their progression rate.\nRESULTS: At least one intermediate SVG lesion was present in 31 of 143 (22%) SVGs in 27 of 80 (34%) patients. Most intermediate lesions were present in the SOS stented SVGs (20 grafts in 19 patients). During a median follow-up of 35 months, angiographic follow-up was available for 28 grafts in 25 patients. Progression (defined as percent diameter stenosis ≥ 70% but \u003c100% at follow-up angiography) was seen in 11 of 28 SVGs (39%) in 11 of 25 patients (44%). Progression rate at 12, 24 and 36 months was 28% and 47% and 84%, respectively. Seven of 11 patients (64%) with intermediate SVG lesion progression presented with an acute coronary syndrome and 8 (73%) underwent PCI. Four of the 28 grafts with intermediate lesions at baseline were 100% occluded at follow-up; all of those SVGs had received a stent in another location in the SVG as part of the SOS trial.\nCONCLUSIONS: Intermediate SVG lesions are common in patients undergoing SVG stenting, have high rates of progression and frequently present with an acute coronary syndrome. Further study of pharmacologic and mechanical treatments to prevent progression of these lesions is needed.","tracks":[{"project":"Allie","denotations":[{"id":"SS1_23561918_2_0","span":{"begin":236,"end":256},"obj":"expanded"},{"id":"SS2_23561918_2_0","span":{"begin":258,"end":261},"obj":"abbr"},{"id":"SS1_23561918_2_1","span":{"begin":278,"end":311},"obj":"expanded"},{"id":"SS2_23561918_2_1","span":{"begin":313,"end":316},"obj":"abbr"}],"relations":[{"id":"AE1_23561918_2_0","pred":"abbreviatedTo","subj":"SS1_23561918_2_0","obj":"SS2_23561918_2_0"},{"id":"AE1_23561918_2_1","pred":"abbreviatedTo","subj":"SS1_23561918_2_1","obj":"SS2_23561918_2_1"}],"attributes":[{"subj":"SS1_23561918_2_0","pred":"source","obj":"Allie"},{"subj":"SS2_23561918_2_0","pred":"source","obj":"Allie"},{"subj":"SS1_23561918_2_1","pred":"source","obj":"Allie"},{"subj":"SS2_23561918_2_1","pred":"source","obj":"Allie"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"Allie","color":"#93bfec","default":true}]}]}}